ARTICLE | Company News
R-Tech Ueno Ltd, Hokkaido University deal
June 22, 2015 7:00 AM UTC
R-Tech partnered with the university to develop R-Tech’s RTU-1096. The biotech will provide the compound to Hokkaido, which will evaluate the therapeutic potential of the compound in treating diabetic retinopathy and diabetic macular edema. The vascular adhesion protein-1 (VAP-1; SSAO) inhibitor is in Phase I testing for atopic dermatitis and psoriasis. R-Tech said financial terms were not disclosed. ...